$0.46
-0.02 (-5.04%)
Open$0.51
Previous Close$0.48
Day High$0.51
Day Low$0.45
52W High$7.28
52W Low$0.42
Volume—
Avg Volume86.7K
Market Cap1.54M
P/E Ratio—
EPS$-1.53
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,661.6% upside
Current
$0.46
$0.46
Target
$8.04
$8.04
$5.03
$8.04 avg
$9.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.65M | 5.72M | 5.36M |
| Net Income | 307.3K | 283.7K | 353.7K |
| Profit Margin | 5.4% | 5.0% | 6.6% |
| EBITDA | 445.8K | 473.3K | 433.9K |
| Free Cash Flow | 346.8K | 407.6K | 312.1K |
| Rev Growth | +24.0% | +14.6% | +14.6% |
| Debt/Equity | 0.71 | 0.92 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |